Advertisement
Advertisement
ADPT
Adaptive Biotechnologies Corporation Common Stock
18.41
USDSponsored
-0.09
-0.49%
Feb 02, 15:59 UTC -5
Closed
After-Market
18.39
-0.02
-0.11%
ADPT Earnings Reports
Positive Surprise Ratio
ADPT beat 21 of 26 last estimates.
81%
Next Report
In 3 Days
Date of Next Report
Feb 05, 2026
Estimate for Q4 25 (Revenue/ EPS)
$60.58M
/-$0.18
Implied change from Q3 25 (Revenue/ EPS)
-35.54%
/-400.00%
Implied change from Q4 24 (Revenue/ EPS)
+27.65%
/-21.74%
Adaptive Biotechnologies Corporation Common Stock earnings per share and revenue
On Nov 05, 2025, ADPT reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.14 USD, resulting in a 140.21% surprise. Revenue reached 93.97 million, compared to an expected 65.94 million, with a 42.52% difference. The market reacted with a -11.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 60.58 million USD, implying an decrease of -400.00% EPS, and decrease of -35.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Adaptive Biotechnologies Corporation Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Adaptive Biotechnologies Corporation Common Stock reported EPS of $0.06, beating estimates by 140.21%, and revenue of $93.97M, 42.52% above expectations.
How did the market react to Adaptive Biotechnologies Corporation Common Stock's Q3 2025 earnings?
The stock price moved down -11.54%, changed from $17.59 before the earnings release to $15.56 the day after.
When is Adaptive Biotechnologies Corporation Common Stock expected to report next?
The next earning report is scheduled for Feb 05, 2026.
What are the forecasts for Adaptive Biotechnologies Corporation Common Stock's next earnings report?
Based on 10
analysts, Adaptive Biotechnologies Corporation Common Stock is expected to report EPS of -$0.18 and revenue of $60.58M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement